Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company issued the 17th through 20th series of stock acquisition rights to raise funds, which were invested mainly in preparations for U.S. clinical trials of CAR-ipsNKT cell therapy scheduled to begin in fiscal 2026. Cash and deposits increased due to proceeds from the issuance of shares upon the exercise of the stock acquisition rights, while there were also expenditures related to research and development, among others.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥0 million (YoY -92.6%) |
| Operating profit | ¥-1,295 million |
| Ordinary income | ¥-1,293 million |
| Profit attributable to owners of the parent | ¥-1,304 million |
| Net income per share | △¥11.70 |
| Operating Margin | △1,541,668.2% |
| Equity ratio | End of the current fiscal period 90.1 / End of previous period 80.6 |
| Total assets | ¥2,604 million |
| Net assets | ¥2,368 million |
| Cash flows from operating activities | ¥-1,365 million |
| Cash flows from investing activities | ¥-1 million |
| Cash flows from financing activities | ¥2,713 million |
| Cash and cash equivalents at end of period | ¥2,156 million |
| Full-year earnings forecast | Net Sales ¥0 million / Operating profit ¥-1,965 million / Ordinary income ¥-1,947 million / Net income ¥-1,949 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Impairment loss | ¥9,398 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥399 thousand / Extraordinary loss Impairment Losses ¥9,398 thousand, Other ¥0 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 138,891,300 |
| Treasury Shares at Period-End | 81 |
| Factors Behind Changes in Business Performance | The company issued the 17th through 20th series of stock acquisition rights to raise funds, which were invested mainly in preparations for U.S. clinical trials of CAR-ipsNKT cell therapy scheduled to begin in fiscal 2026. Cash and deposits increased due to proceeds from the issuance of shares upon the exercise of the stock acquisition rights, while there were also expenditures related to research and development, among others. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that it raised funds by issuing stock acquisition rights and invested the proceeds mainly in preparations for U.S. clinical trials of CAR-ipsNKT cell therapy scheduled to begin in fiscal 2026. It also states that the financing environment remains cautious due to interest-rate trends and changes in investors’ risk appetite, among other factors.